The AHSN Network has been announced as a Founding Collaborator of The Sustainable Medicines Partnership (SMP), a not-for-profit, global collaboration which undertakes projects to make the use of medicines more sustainable and less wasteful.
The partnership includes leading pharma, generic and retail medicines manufacturers, distributors, supply chain, technology providers, healthcare, hospitals, pharmacy, researchers, academia, policymakers and changemakers.
Pete Waddingham, Net Zero Lead at The AHSN Network, said:
“We are delighted to be part of the Sustainable Medicine Partnership. There are a number of reasons why we wanted to part of this partnership. Firstly, the AHSN Network are actively involved in both national and local programmes which impact on patients and the medicines they take.
“The AHSN Network works with innovators that can directly contribute to better medicine use and also support the NHS supply chain. These range from organisations that help improve patient communication and understanding of their care, keeping people at home and monitored, through to innovation that can help the supply chain reduce its energy use or improve their logistics.
“Finally, we will only be able to tackle this climate emergency if we work in collaboration with others. The SMP gives us this opportunity, on the subject of medicines, along with some great partnership organisations.
“I am particularly looking forward to exploring what opportunities the SMP can bring to enhancing a number of our national programmes including polypharmacy or lipid management.”
Through a four year programme of priority actions, the Sustainable Medicines Partnership aims to reduce the waste of medicines and from medicines – reducing healthcare emissions and increasing health equity globally.
AHSNs support the NHS to deliver its Net Zero commitments through identifying new products, technologies and ways of working to support this agenda. To do this, we have developed our AHSN Network Environmental Sustainability Strategy.
The Network’s Polypharmacy Programme aims to increased confidence amongst primary care prescribing workforce and patients in order to safely stop medicines identified to be inappropriate or unnecessary, Studies have shown that that over 50% of older people are prescribed a medicine with more harm than benefit. In England there were more than 800k people on 10 or more medicines and these are 300% more likely to be admitted to hospital.
The national lipids optimisation programme aims to improve the management of cholesterol, increase the detection of those with Familial Hypercholesterolaemia and optimise the use of all medicines for patients.
Pete continued: “As set out in a recent report, overprescribing medication results in millions of packets of medicine wasted each year, which consumes energy, plastics and other resources… the production and use of some medicines can generate significant greenhouse gas emissions and so contribute to climate change. Reducing [this] will help the NHS fulfil its commitment to become carbon net zero.
Alanguage is not English, people with lower levels of health literacy, accessibility issues, or people just wanting simple, easy to understand information on their medication can all benefit if we work in collaboration with innovators, patients and industry.”
Find out more about the SMP at www.yewmaker.com/smp
[1] https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1019475/good-for-you-good-for-us-good-for-everybody.pdf
[2] https://www.ons.gov.uk/peoplepopulationandcommunity/householdcharacteristics/homeinternetandsocialmediausage/bulletins/internetaccesshouseholdsandindividuals/2020
Lesley Bull, a South London GP and our 1000th delegate chats to Lois-Hooper Ainsworth, Programme Coordinator on the National Polypharmacy Programme, about why she registered for the Health Innovation Network Polypharmacy Action Learning Set, what she got out of it and why other GPs should attend. Lesley Bull So, Lesley, could you tell [...]
Jo Barosa is Account Director at Qbtech UK. Qbtech is a market leading provider of innovative objective tests for assessing and treating ADHD, changing the landscape of ADHD care. Driven by its mission to improve the lives of people with ADHD, Qbtech supports by providing digital and clinical solutions to improve clinical decision making, service [...]
Dr Cheryl Crocker, interim Chief Operating Officer at the Health Innovation Network, explains the vital role innovation plays to not only reduce waiting lists and improve access to care, but to decrease system pressure by improving people’s health and keeping them well for longer. The new Government has rightly declared its focus on moving the [...]
